Strumento inattivo

Altre lingue Catalyst Biosciences Inc Nasdaq

Azioni

US14888D1090

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

2023	Beijing Continent Pharmaceutical Co., Ltd. ha completato l'acquisizione di Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in una transazione di fusione inversa.	CI
2023	Catalyst Biosciences, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Catalyst Biosciences : Investor presentation 556.6 KB	11/05
Catalyst Biosciences : Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Form 8-K	09/05
Catalyst Biosciences : Notification of Conclusion of License Agreement by Gyre Pharmaceuticals Co - Form 8-K	08/05
Catalyst Biosciences : Investor presentation 556.8 KB	03/05
Catalyst Biosciences : Investor presentation 556.2 KB	02/05
Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K	06/12
Catalyst Biosciences : GNI Group Updates Full Year 2023 Consolidated Earnings Forecast - Form 8-K	06/11
Catalyst Biosciences : Change in Certifying Accountants - Form 8-K	02/11
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split	30/10/23
Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	30/10/23
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	30/10/23
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.	30/10/23
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.	27/10/23
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc	29/08/23
North American Morning Briefing : China Trouble Hits Sentiment	18/08/23
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders	25/07/23
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO	22/07/23
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Catalyst Biosciences Inc Nasdaq

Azioni

US14888D1090

Altre lingue

Filtri